| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
866.07(B) |
| Last
Volume: |
3,374,911 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,771,329 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
50 |
93 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Alvarez Ralph |
Director |
– • – |
2017-02-21 |
4 |
A |
$80.36 |
$10,929 |
D/D |
136 |
35,362 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2017-02-21 |
4 |
A |
$80.36 |
$9,643 |
D/D |
120 |
2,160 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2017-02-17 |
4 |
S |
$80.27 |
$18,462,790 |
D/D |
(230,000) |
125,125,804 |
|
- |
|
| Zulueta Alfonso G |
SVP& Pres., Emerging Markets |
• – – |
2017-02-06 |
4 |
S |
$77.66 |
$1,164,900 |
D/D |
(15,000) |
45,583 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2017-02-03 |
4 |
AS |
$77.47 |
$301,513 |
D/D |
(3,892) |
38,292 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2017-02-02 |
4 |
AS |
$76.97 |
$559,572 |
D/D |
(7,270) |
42,184 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2017-02-02 |
4 |
S |
$77.52 |
$155,040 |
D/D |
(2,000) |
886 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$692,423 |
D/D |
(8,989) |
49,454 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,463 |
58,443 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$109,383 |
D/D |
(1,420) |
15,941 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,073 |
17,361 |
|
- |
|
| Zulueta Alfonso G |
SVP& Pres., Emerging Markets |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$240,873 |
D/D |
(3,127) |
60,583 |
|
- |
|
| Zulueta Alfonso G |
SVP& Pres., Emerging Markets |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,659 |
63,710 |
|
- |
|
| Walsh Fionnuala M |
SVP, Global Quality |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$166,770 |
D/D |
(2,165) |
67,144 |
|
- |
|
| Walsh Fionnuala M |
SVP, Global Quality |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,610 |
69,309 |
|
- |
|
| Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$364,429 |
D/D |
(4,731) |
137,022 |
|
- |
|
| Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,244 |
141,753 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2017-02-01 |
4 |
D |
$77.03 |
$372,594 |
D/D |
(4,837) |
104,563 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,244 |
109,400 |
|
- |
|
| Peterson Barton R |
Sr. VP, Corp. Affairs & Comm. |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$203,821 |
D/D |
(2,646) |
108,312 |
|
- |
|
| Peterson Barton R |
Sr. VP, Corp. Affairs & Comm. |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,634 |
110,958 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$352,027 |
D/D |
(4,570) |
91,470 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,732 |
96,040 |
|
- |
|
| Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$555,771 |
D/D |
(7,215) |
155,153 |
|
- |
|
| Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,366 |
162,368 |
|
- |
|
1436 Records found
|
|
Page 41 of 58 |
|
|
3.66 (0.4%) 
